On November 11, Finnegan client International CSRC Investment Holdings Co. announced that Sanofi’s U.S. subsidiary Genzyme Corp agreed to pay $180 million to resolve a licensing dispute and to end the arbitrations they initiated over royalties for patents directed to treatments for Pompe disease, a rare neuromuscular disorder. The arbitrations were initiated by Genzyme through the American Arbitration Association (AAA) after Genzyme claimed that their royalty obligations expired earlier than the initial licensing agreement terms.
Read “Sanofi Unit To Pay $180M in Disease Treatment Patent Fight”
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.